Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
01 Dezember 2021 - 11:09PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of December, 2021
Commission File Number 001-35463
Taro Pharmaceutical Industries Ltd.
(Translation of registrant’s name into English)
14 Hakitor Street, Haifa Bay 2624761, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____
|
|
|
Taro Pharmaceutical Industries Ltd.
|
c/o Taro Pharmaceuticals U.S.A., Inc.
|
Three Skyline Drive
|
Hawthorne, New York 10532
|
(NYSE: TARO)
|
FOR IMMEDIATE RELEASE
CONTACT:
|
|
William J. Coote
VP, Chief Financial Officer
(914) 345-9001
William.Coote@taro.com
|
|
TARO APPOINTS NEW CHIEF FINANCIAL OFFICER
Hawthorne, NY, December 1, 2021 — Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) today announced the appointment of William J. Coote as Vice President, Chief Financial Officer and Chief Accounting Officer, effective today.
Mr. Coote has over 25 years of significant financial executive experience; most recently serving as Taro’s AVP, Treasurer and Business Finance since 2008.
Prior to joining Taro, Mr. Coote has held progressively responsible positions with a variety of global companies such as Bowne & Co., Prudential Realty, Merrill Lynch, and Ernst & Young. Throughout his career, he has been accountable for areas such as: Accounting, Treasury, Budgeting, Financial Planning and Analysis, Acquisitions, Investor Relations, Financial and SEC Reporting.
Regarding the appointment, Mr. Uday Baldota, Taro’s CEO, commented, “I am excited to have Bill lead our financial and accounting teams at Taro. Bill is a successful Taro leader; he brings a strong track record of accomplishment and diversified experience, combined with continuity, as we execute on our strategy.”
************************
About Taro
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: December 1, 2021
TARO PHARMACEUTICAL INDUSTRIES LTD.
By: /s/ Uday Baldota
Name:Uday Baldota
Title:Chief Executive Officer and Director
Taro Pharmaceutical Indu... (NYSE:TARO)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Taro Pharmaceutical Indu... (NYSE:TARO)
Historical Stock Chart
Von Jan 2024 bis Jan 2025